Choice of neuroprotective therapy regimens in patients with chronic cerebral ischemia, taking into account the synergy of drug interactions

Gromova O.A.; Torshin I.Yu.; Putilina M.V.; Semenov V.A.; Rudakov K.V.

doi:https://doi.org/10.17116/jnevro202012008142

Gromova O.A.

Federal Research Center «Computer Science and Control»

ORCID: 0000-0002-7663-710X

Torshin I.Yu.

Federal Research Center «Computer Science and Control»

ORCID: 0000-0002-2659-7998

Putilina M.V.

Pirogov Russian National Research Medical University

ORCID: 0000-0002-8655-8501

Semenov V.A.

Kemerovo State Medical University

Rudakov K.V.

Institute of Pharmacoinformatics;
Center for Big Data Storage and Analysis of Moscow State University

Choice of neuroprotective therapy regimens in patients with chronic cerebral ischemia, taking into account the synergy of drug interactions

Authors:

Gromova O.A., Torshin I.Yu., Putilina M.V., Semenov V.A., Rudakov K.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8): 42‑50

DOI: 10.17116/jnevro202012008142

Read: 14625 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Gromova OA, Torshin IYu, Putilina MV, Semenov VA, Rudakov KV. Choice of neuroprotective therapy regimens in patients with chronic cerebral ischemia, taking into account the synergy of drug interactions. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8):42‑50. (In Russ.)
https://doi.org/10.17116/jnevro202012008142

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

Optimization of the choice of neuroprotective treatment regimens in patients with chronic cerebral ischemia that takes into account the synergy of drug interactions gives the doctor an opportunity for personalized approach that increases the effectiveness of treatment.

MATERIAL AND METHODS

Differential chemoreactomic analysis of the synergism of ethyl methyl hydroxypyridine succinate (EMHPS) and a number of monocomponent neuroprotective agents (piracetam, vinpocetine, citicoline, choline alfoscerate); proteomic analysis of polypeptide neuroprotectors (cerebrolysin, etc.); an expert analysis of multicomponent neuroprotector Cytoflavin.

RESULTS

Piracetam, citicoline (Neupilept) and choline alfoscerate (Cereton) effectively enhance the pharmacological properties of EMHPS and vice versa. Expert assessments of the synergism between the properties of EMHPS, polypeptide neuroprotectors (cerebrolysin) and other multicomponent drugs (cytoflavin), which are also used in adjuvant therapy with EMHPS, are presented.

CONCLUSION

In real clinical practice, of particular interest is the objectification of the appointment of combined therapy regimens. This study indicates that EMHPS can provide a favorable background for maximizing the effectiveness of therapy when used with other drugs.

Keywords:

ethylmethylhydroxypyridine succinate

piracetam

choline alfoscerate

citicoline

peptide preparations

cytoflavin

pharmacoinformatics

data mining

synergism

Authors:

Gromova O.A.

Federal Research Center «Computer Science and Control»

ORCID: 0000-0002-7663-710X

Torshin I.Yu.

Federal Research Center «Computer Science and Control»

ORCID: 0000-0002-2659-7998

Putilina M.V.

Pirogov Russian National Research Medical University

ORCID: 0000-0002-8655-8501

Semenov V.A.

Kemerovo State Medical University

Rudakov K.V.

Institute of Pharmacoinformatics;
Center for Big Data Storage and Analysis of Moscow State University

Received:

01.06.2020

Accepted:

08.06.2020

Close metadata

References:

Gusev EI, Skvorcova VI. Ishemija golovnogo mozga. M: Medicina 2001;326. (In Russ.).
Prikaz Ministerstva zdravoohranenija Rossijskoj Federacii ot 29 dekabrja 2012 g. № 1740n «Ob utverzhdenii standarta specializirovannoj medicinskoj pomoshhi pri infarkte mozga». (In Russ.).
Putilina MV, Teplova NV. Algorithms for rational pharmacotherapy of chronic brain ischemia. Nervous disease. 2019;1:11-16. (In Russ.).
Voronina TA. Rol’ oksidativnogo stressa i antioksidantov pri dezadaptacii razlichnogo geneza. Farmacija i farmakologija. 2015;3(5):8-17. (In Russ.). https://doi.org/10.19163/2307-9266-2015-3-5s.
Gromova OA, Torshin IY, Fedotova LE, Gromov AN. Chemoreactome analysis of ethylmethylhydroxypyridine succinate. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(3):53-60. (In Russ.)
Torshin IJu, Gromova OA, Sorokin AI, Semenov VA, Stahovskaja LV. Hemotranskriptomnyj analiz molekuly jetilmetilgidroksipiridina sukcinata v kontekste postgenomnoj farmakologii. Nevrologija, psihiatrija, psihosomatika. 2020;2 (v pechati). (In Russ.).
Ivanov I.V. Internal control of drug safety in the health facilities. Remedium. 2018;5:64-67. (In Russ.). https://doi.org/10.21518/1561-5936-2018-5-64-67.
Torshin IYu. Bioinformatics in the post-genomic era: physiology and medicine. Nova Biomedical Books, NY, USA. 2007. ISBN 1-60021-752-4.
Torshin IY, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. part 1: factorization approach. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2017;27:1:16-28. https://doi.org/10.1134/S1054661817010151
Torshin IYu, Rudakov KV. On the Application of the Combinatorial Theory of Solvability to the Analysis of Chemographs. Part 1: Fundamentals of Modern Chemical Bonding Theory and the Concept of the Chemograph. Pattern Recognition and Image Analysis. 2014;24(1):11-23. https://doi.org/10.1134/S1054661814010209
Torshin IY., Rudakov, K.V. On metric spaces arising during formalization of problems of recognition and classification. Part 2: Density properties. Pattern Recognit. Image Anal. 2016;26:483-496. https://doi.org/10.1134/S1054661816030202
Torshin IY. On solvability, regularity, and locality of the problem of genome annotation. Pattern Recognit. Image Anal. 2010;20:386-395. https://doi.org/10.1134/S1054661810030156
Torshin IY. The study of the solvability of the genome annotation problem on sets of elementary motifs. Pattern Recognit. Image Anal. 2011;21:652-662. https://doi.org/10.1134/S1054661811040171
Gromova OA, Torshin IY, Stelmashuk EV, Alexandrova O. P., Pronin, A. V., Gogoleva I. V., Khaspekov L. G. A study of the neuroprotective effect of mexidol on the cell model of glutamate stress. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(12):71-77. (In Russ.). https://doi.org/10.17116/jnevro201711712171-77]
Wang DP, Lv QL, Lin Q, Kang K, Jin KY, Hai J. The Cannabinoid Receptor Agonist WIN55,212-2 Ameliorates Hippocampal Neuronal Damage After Chronic Cerebral Hypoperfusion Possibly Through Inhibiting Oxidative Stress and ASK1-p38 Signaling. Neurotox Res. 2020 Apr;37(4):847-856. https://doi.org/10.1007/s12640-019-00141-8. PMID:31808139
Gromova OA, Kalacheva AG, Grishina TR, Bogacheva TE, Demidov VI, Torshin IY. Neurotrophic peptides of cerebrolysin as a basis for anticonvulsant effect of the drug. Zh Nevrol Psikhiatr Im SS Korsakova. 2016;116(3):55-62. (In Russ.). https://doi.org/10.17116/jnevro20161163155-62
Gromova OA, Torshin IY, Gogoleva IV, et al. Pharmacokinetic and Pharmacodynamic Synergism Between Neuropeptides and Lithium in the Neurotrophic and Neuroprotective Action of Cerebrolysin. Zh Nevrol Psikhiatr Im SS Korsakova. 2015;115(3):65-72. (In Russ.). https://doi.org/10.17116/jnevro20151153165-72
Gromova OA, Torshin IIu, Gogoleva IV. Mechanisms of neurotrophic and neuroprotective effects of cerebrolysin in cerebral ischemia. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(3 Pt 2):43-50. PMID: 24781241. (In Russ.).
Bradshaw RA, Murray-Rust J, Ibáñez CF, McDonald NQ, Lapatto R, Blundell TL. Nerve growth factor: structure/function relationships. Protein Sci. 1994 Nov;3(11):1901-1913.
Yamada N, Katsuura G, Tatsuno I, Kawahara S, Ebihara K, Saito Y, Nakao K. Orexins increase mRNA expressions of neurotrophin-3 in rat primary cortical neuron cultures. Neurosci Lett. 2009 Jan 30;450(2):132-135. https://doi.org/10.1016/j.neulet.2008.11.028
Vrontakis ME. Galanin: a biologically active peptide. Curr Drug Targets CNS. Neurol Disord. 2002 Dec;1(6):531-541. https://doi.org/10.2174/1568007023338914
Suarez V, Guntinas-Lichius O, Streppel M, Ingorokva S, Grosheva M, Neiss WF, Angelov DN, Klimaschewski L. The axotomy-induced neuropeptides galanin and pituitary adenylate cyclase-activating peptide promote axonal sprouting of primary afferent and cranial motor neurones. Eur J Neurosci. 2006 Sep;24(6):1555-1564. https://doi.org/10.1111/j.1460-9568.2006.05029.x
Georgy GS, Nassar NN, Mansour HA, Abdallah DM. Cerebrolysin Ameloriates Cognitive Deficits in Type III Diabetic Rats. PLoS One. 2013 Jun 19;8(6):e64847. https://doi.org/10.1371/journal.pone.0064847
Shabanov P.D. Cytoflavin in the treatment of asthenic conditions. Toolkit for doctors. SPb: VMEDA 2012. (In Russ.).
Sazonov IE, Kudinov AA, Fedotova EP. Study cytoflavin dose-dependent effect in the treatment of acute ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2):64-67. (In Russ.). https://doi.org/10.17116/jnevro20171172164-67
Mazin PV, Sheshunov IV, Mazina NK. Meta-analytic assessment of parenteral cytoflavin effectiveness in different neurologic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(3):28-39. (In Russ.). https://doi.org/10.17116/jnevro20171173128-39
Gromova OA, Torshin IYu, Fedotova LE. Geriatric information analysis of the molecular properties of mexidole. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2017;9(4):46-54. (In Russ.). https://doi.org/10.14412/2074-2711-2017-4-46-54